The Coalition for Epidemic Preparedness Innovations, CEPI, and Moderna have entered into a strategic partnership that will harness Moderna’s mRNA platform to accelerate the development of vaccines against viral disease outbreaks that threaten global health. The work undertaken as part of this partnership could expand the infectious disease targets for mRNA vaccine technology and strengthen pandemic preparedness and public health efforts in alignment with the 100 Days Mission, a global goal to compress vaccine development timelines to 100 days. Stephane Bancel, CEO of Moderna, said: “We are pleased to announce our strategic partnership with CEPI, harnessing the power of Moderna’s mRNA platform to accelerate the development of mRNA vaccines against viral disease outbreaks that pose global public health threats. Our mRNA Access program reinforces our dedication to public health by offering researchers the opportunity to utilize our mRNA technology in the development of vaccines for emerging and neglected infectious diseases. We believe this program can play a key role in helping the next generation of researchers and engineers to advance mRNA science.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRNA:
- Options Volatility and Implied Earnings Moves This Week, October 30 – November 03, 2023
- Mixed Day for Vaccine Stocks as Terrible News Emerges
- Moderna price target lowered to $100 from $125 at TD Cowen
- Moderna doses first participant in Phase 3 study of mRNA-1083
- Moderna announces first participant dosed in Phase 3 flu/COVID combo vax study